Hidrasec (Racecadotril)

Hidrasec is indicated for the symptomatic relief of acute diarrhea, a common gastrointestinal disturbance that can affect both children and adults.

• Short‑term management of watery stools associated with acute gastroenteritis.
• Adjunct therapy to oral rehydration solutions in mild to moderate dehydration.
• Use in pediatric patients when rapid reduction of stool frequency is desired.
• Support for travelers experiencing sudden onset diarrhea in non‑hospital settings.
• Option for patients seeking non‑opioid antidiarrheal treatment.

• Racecadotril, the active component of Hidrasec, is a prodrug that is rapidly converted to thiorphan, a potent inhibitor of intestinal enkephalinase. By blocking this enzyme, endogenous enkephalins accumulate in the gut lumen, activating opioid receptors on enteric neurons. This activation reduces cyclic AMP‑mediated chloride secretion, leading to decreased intestinal fluid loss without affecting intestinal motility and helps restore fluid balance.

Adverse reactions to Hidrasec are usually mild and transient, but clinicians should be aware of rare but potentially serious events that may require medical attention.

Common

• Nausea or mild stomach discomfort, typically occurring shortly after ingestion.
• Headache, often described as mild to moderate intensity.
• Dizziness or light‑headedness, which usually resolves without intervention.
• Flatulence or abdominal bloating, which may accompany the antidiarrheal effect.

Serious

• Severe allergic reaction such as rash, itching, swelling of the face or limbs, or difficulty breathing (anaphylaxis).
• Persistent vomiting that interferes with oral rehydration and fluid balance.
• Marked abdominal pain that is sudden, severe, or accompanied by guarding.
• Signs of worsening dehydration despite therapy, including dry mouth, reduced urine output, or dizziness on standing.

When considering Hidrasec, certain precautions should be observed to ensure safe use, especially in vulnerable populations.

• Assess for known hypersensitivity to racecadotril or any component before initiating therapy.
• Use with caution in patients with severe renal impairment, as drug clearance may be reduced.
• Avoid in children younger than three months of age due to limited safety data.
• Monitor fluid and electrolyte status in patients with ongoing diarrhea to prevent dehydration.
• Do not combine with other antidiarrheal agents without medical advice, as additive effects may occur.
• Consider postponing use during pregnancy until safety is established.

Hidrasec may interact with other medicines, and awareness of potential interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concurrent use with other opioid‑type antidiarrheal agents (e.g., loperamide) due to overlapping mechanisms.
• Combining with drugs that significantly alter gastrointestinal motility, such as prokinetics, without supervision.

Use with caution

• Co‑administration with medications cleared renally (e.g., certain antibiotics) in patients with impaired kidney function.
• Use alongside oral rehydration solutions containing high electrolyte concentrations, monitoring for electrolyte imbalance.
• Concomitant use with antihistamines or sedatives may enhance central nervous system side effects like dizziness.
• If the patient is receiving diuretics, monitor serum electrolytes closely to avoid additive loss of potassium or sodium.